Safety of COVID-19 vaccines in subjects with solid tumor cancers receiving immune checkpoint inhibitors
The incidence of severe immune-related adverse events (irAEs) in cancer subjects receiving immune checkpoint inhibitors (ICIs) following COVID-19 vaccination and the relationship between the incidence of severe irAE and the interval between COVID-19 vaccination and ICI dose have not been established...
Saved in:
Main Authors: | Danielle Gilbert (Author), Junxiao Hu (Author), Theresa Medina (Author), Elizabeth R. Kessler (Author), Elaine T. Lam (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2023-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy and safety of oncolytic virus combined with chemotherapy or immune checkpoint inhibitors in solid tumor patients: A meta-analysis
by: Xiangxing Liu, et al.
Published: (2022) -
Follow-up Care for Patients Receiving Immune Checkpoint Inhibitors
by: Liyan Zhang, et al.
Published: (2021) -
What's new in molecular genetic pathology 2022: immune checkpoint inhibitor biomarkers and select solid tumors
by: Patricia C. Tsang, et al.
Published: (2022) -
Prognostic impact of metformin in solid cancer patients receiving immune checkpoint inhibitors: novel evidences from a multicenter retrospective study
by: Jiaxin Wang, et al.
Published: (2024) -
Immune-Related Adverse Events in the Older Adult with Cancer Receiving Immune Checkpoint Inhibitor Therapy
by: Matthew D Biniakewitz, et al.
Published: (2021)